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Abstract
 
The importance of the hematopoietic protooncogene Vav1 in immune cell function is widely
recognized, although its regulatory mechanisms are not completely understood. Here, we ex-
amined whether Vav1 has a nuclear function, as past studies have reported its nuclear localiza-
tion. Our findings provide a definitive demonstration of Vav1 nuclear localization in a receptor
stimulation–dependent manner and reveal a critical role for the COOH-terminal Src homol-
ogy 3 (SH3) domain and a nuclear localization sequence within the pleckstrin homology do-
main. Analysis of DNA-bound transcription factor complexes revealed nuclear Vav1 as an inte-
gral component of transcriptionally active nuclear factor of activated T cells (NFAT)- and
nuclear factor (NF)
 
 
 
B-like complexes, and the COOH-terminal SH3 domain as being critical
in their formation. Thus, we describe a novel nuclear role for Vav1 as a component and facili-
tator of NFAT and NF
 
 
 
B-like transcriptional activity.
Key words: Vav • nuclear translocation • nuclear factor of activated T cells • calcium inﬂux • 
protein subdomains
 
Introduction
 
Engagement of immune receptors initiates a wide variety
of biochemical responses that lead to the activation of T,
B, and mast cells. Activation of tyrosine kinases is the
event most proximal to receptor engagement and results in
the subsequent assembly of signaling modules comprised
of multiple tyrosine phosphorylated proteins including ki-
nases, phosphatases, adaptors, and other effector proteins
like the 95-kD protooncogene Vav1 (1–7). Vav 1 is ex-
pressed exclusively in hematopoietic cells whereas Vav2
and Vav3 are ubiquitous homologues that are coupled to
several growth factor receptors (8, 9). Vav 1 is a structur-
ally complex protein containing a Calponin homology do-
 
main (CH),
 
*
 
 an acidic region, a Dbl homology domain
 
(DH), a pleckstrin homology domain (PH), a cysteine-rich
domain, and three Src homology domains (SH3-SH2-SH3)
(10). Via its DH domain Vav1 has been shown to catalyze
the GDP-GTP exchange of Rho family GTPases with
some preference for the Rac GTPase (11). Interestingly,
Vav1 also contains two putative nuclear targeting se-
quences (NLS) whose presence is suggestive of Vav1 nu-
clear localization but whose function has not formally
been demonstrated.
In recent years gene targeting deletion experiments re-
vealed the importance of Vav1 in T lymphocyte develop-
ment and function. A profound defect in positive and nega-
tive selection of T cells has been described (12–14) that
results in low numbers of mature T cells in the periphery.
The cells that manage to escape the thymus are impaired in
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S
 
-transferase; JNK, c-jun NH
 
2
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antigen-induced calcium signals and proliferation. These cells
also show decreased activation of nuclear factor of activated
T cells (NFAT)- and NF
 
 
 
B-transcription factors and re-
duced expression of activation markers in response to TCR
stimulation. Moreover, the cells failed to form actin-depen-
dent patches and caps that are the hallmark of the immune
synapse (15–18). Many of these defects may be explained by
the role of Vav1 in the activation of Rho family GTPases,
which function to reorganize the actin cytoskeleton, and by
its regulation of phospholipase C (PLC)
 
 
 
-dependent calcium
responses as seen in Vav 1
 
 
 
/
 
 
 
 mast cells (19).
Whereas it is clear that Vav1 localizes to the plasma
membrane in activated T (4), B (7), and mast cells (20),
early studies suggested a possible nuclear localization for
Vav both in rat basophilic leukemia (RBL) cells and in T
lymphoid cells upon prolonged Fc
 
 
 
RI engagement or pro-
lactin stimulation, respectively (21, 22). Subcellular frac-
tionation, immunofluorescence, and electron microscopic
studies also indicated the partial nuclear localization of Vav
in T cell lymphomas (Jurkat), granulocytes (HL60), and
megakaryoblastic cells (UT7) even in the absence of any
stimulus (23–25). Several studies have also shown an inter-
action of Vav with nuclear proteins. These include Ku-70,
a component of the DNA-dependent protein kinase com-
plex (23), the ribonucleoprotein hnRNPC, involved in
RNA maturation and nucleocytoplasmic transport (25),
and ENX-1, the human homologue of a member of the
polycomb group of proteins involved in transcriptional
regulation of Drosophila homeobox genes (26, 27). While
the SH2 domain of Vav was demonstrated to be essential in
receptor proximal events by mediating its plasma mem-
brane localization and interaction with a linker for activa-
tion of T cells (LAT)-organized signaling module both a
leucine stretch within the NH
 
2
 
-terminal CH domain (re-
sponsible for the interaction with Enx1) and the COOH-
terminal SH3 (hnRNP and Ku70 interacting region) have
been demonstrated to be domains that interact with nuclear
proteins. Altogether, these results suggested a molecular
function for Vav1 in the nucleus.
In this study we undertake the challenge of elucidating a
nuclear role for Vav1. First, we demonstrate unequivocally
that Vav1 translocates to the nucleus upon prolonged stim-
ulation of the Fc
 
 
 
RI and that its movement to the nucleus
is dependent on one of the two previously identified puta-
tive NLS. Furthermore, we find that Vav1 nuclear target-
ing is also under the control of the COOH-terminal SH3
(C-SH3) domain, which serves to sequester its presence in
the cytoplasm. Most importantly, however, is the finding
that Vav1 is a nuclear partner of the transcription factor
NFAT (28) and a nuclear factor (NF)
 
 
 
B-like factor (29).
For NFAT, Vav1 serves to facilitate its movement to the
nucleus and forms part of a transcriptionally active complex
that binds the NFAT binding site of the IL-2 promoter.
 
Materials and Methods
 
Antibodies and Reagents.
 
Supernatants from the hybridoma
Hi-DNP-
 
 
 
-26.82 were used as a source of anti-DNP specific
IgE for sensitization experiments (1/200). Antibodies to NFATp
and Vav1 were purchased from Upstate Biotechnology. Anti-
body to Vav 1 was also provided by Dr. X. Bustello (University
of Salamanca, Salamanca, Spain). The monoclonal anti-CD3
(UCHT1), anti-Myc tag (9E10), and anti-CD28 were provided
by Dr. G. Bismuth (ICGM, Paris, France), Dr. S. Fischer
(ICGM), and Dr. D. Olive (U119 Inserm, Marseille, France), re-
spectively. Monoclonal antibodies to NFATc and poly (ADP-ri-
bose) polymerase (PARP) and polyclonal antibody to c-jun NH
 
2
 
terminal kinase (JNK) were purchased from Santa Cruz Biotech-
nology, Inc. Antibodies to glutathione 
 
S
 
-transferase (GST) and
c-Jun (c-Jun was a gift of V. Tybulewicz, National Institute of
Medical Research, Mill Hill, UK) were provided by Dr. P.
Mayeux (ICGM).
 
Cell Culture and Stimulation.
 
Bone marrow–derived mast cells
(BMMCs) from Vav-null and from wild-type (wt) litter mates
were generated from femur bone marrow by incubation in IL3
for 4 wk as described previously (30). Mast cell differentiation and
phenotype were confirmed by toluidine blue staining. Purity was
usually more than 95%. Based on our previous experiments,
monitoring exocytosis at the single cell level by annexin V bind-
ing, more than 80% of the cells degranulated after IgE cross-link-
ing (31). RBL-2H3 cells were maintained as reported (29). For
stimulation, cells were sensitized for 1 h in culture medium (2 
 
 
 
10
 
6 
 
cells/ml) with DNP-specific IgE. After 1 h, the cells were
washed and challenged with DNP-human serum albumin (HSA)
(100 ng/2 
 
 
 
 10
 
6
 
cells/ml) for the indicated period of time at
37
 
 
 
C. Jurkat cells were maintained as described previously (32).
Stimulation was performed with a combination of anti-CD3
mAb (10 
 
 
 
g/ml) and anti-CD28 (10 
 
 
 
g/ml).
 
DNA Constructs.
 
pEF-Myc-tagged Vav1 was provided by
Dr. A. Altman (La Jolla Institute for Allergy and Immunology,
San Diego, CA). pEF-Myc–tagged Vav1 deleted of the CSH3
domain (delCSH3), of the NSH3 domain (delNSH3), of the first
consensus NLS sequence (delNLS1), or the second NLS se-
quence (delNLS2) were obtained by recombinant DNA technol-
ogy by replacing the wt fragments with an appropriate mutated
fragment generated by PCR as follows: for delCSH3: the wt
fragment between Bsu36I at 1,988 bp and BstXI at 2,508 bp in
the ORF was replaced by a fragment that deleted amino acids
787 to 846. For delNSH3: the fragment between AflIII at 1,406
bp and Bsu36I at 1,988 bp of the ORF was replaced by the cor-
responding fragment deleted of amino acids 605–662. For
delNLS1 and delNLS2: the fragment between AflIII-Bsu36I was
replaced by the corresponding fragment deleted of amino acids
487–494 and 576–589, respectively. pEFdelNLS1CSH3 and
pEFdelNLS2CSH3 were constructed by the additional replace-
ment of the Bsu36I-BstXI fragment in delNLS1and delNLS2 by
the corresponding fragment isolated from delCSH3.
 
Immunofluorescence Staining and Confocal Analysis.
 
RBL cells
and BMMC-derived mast cells were processed for confocal imag-
ing as described previously (32). Antibodies to –Vav and myc
were used at a 1/500 dilution followed by incubation with don-
key anti–mouse F(ab)
 
 
 
2
 
 coupled to FITC (Jackson Immuno-
Research Laboratories; 1/100 dilution). The coverslips were
mounted in Mowiol with Dabco antifading and the nucleus was
labeled with DAPI. Immunofluorescence was analyzed by confo-
cal laser-scanning microscopy with high numerical aperture lens
(63 
 
 
 
 1, 3NA; Bio-Rad Laboratories) at 522/535 wavelength.
Images were single optical sections obtained as TIFF files.
 
Subcellular Fractionation and Nuclear Extracts.
 
All procedures
were performed at 4
 
 
 
C. For nucleus and cytoplasmic fraction-
ation procedures, cells were lysed (5 
 
 
 
 10
 
7
 
 cells/ml) in buffer A 
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(10 mM Hepes, pH 7.6, 15 mM KCl, 2 mM MgCl2, 1 mM
DTT, 0.1 mM EDTA, 0.05% NP40, and protease inhibitors).
Nuclei were pelleted by low speed centrifugation (1,000 
 
g
 
 for 10
min at 4
 
 
 
C) and resuspended in buffer C (50 mM Hepes, pH 7.8,
50 mM KCl, 1 mM DTT, 0.1 mMEDTA, and 10% glycerol and
protease inhibitors). The nuclei were lysed (5 
 
 
 
 10
 
7 
 
nuclei/ml)
by addition of 10% (vol/vol) of 3 M ammonium sulfate, pH 7.9
followed by rotation at 4
 
 
 
C for 30 min. The nuclear debris was
pelleted at 100,000 
 
g
 
 for 15 min. Soluble proteins in the nuclear
supernatant were precipitated by addition of an equal volume of
ammonium sulfate 3 M, pH 7.9, pelleted by centrifugation at
50,000 
 
g
 
 for 10 min and resuspended in 100 
 
 
 
l of buffer C.
The cytoplasmic fraction was recovered after pelleting of the
nuclei. The latter was stabilized by addition of 10% (vol/vol)
 
glycerol and 10% (vol/vol) of buffer B (0.3 M Hepes, pH 7.8, 1.4 M
KCl, 30 mM MgCl
 
2
 
). Soluble proteins were recovered by cen-
trifugation at 200,000 
 
g
 
 for 15 min. The recovered proteins were
precipitated by adding an equal volume of 3 M ammonium sul-
fate, pH 7.9, and pelleted at 100,000 
 
g
 
 for 10 min. The precipi-
tated cytoplasmic proteins were resuspended in 100 
 
 
 
l of buffer
C. Quantitation of protein concentrations in the extracts was de-
termined by the BCA protein assay (Pierce Chemical Co.). To
extract both soluble and DNA embedded nuclear proteins for the
electrophoretic mobility shift assays, nuclear extracts were pre-
pared according to the method of Dignam et al. (salt extraction
with 370 mM NaCl) as described previously (29, 33).
 
Immunoblotting, Gel Retardation Assays, and Cross-linking Experi-
ments.
 
Immunoprecipitations and immunoblotting were per-
formed by previously described procedures (32) and immuno-
blotted proteins were revealed by enhanced chemiluminescence
(Amersham Pharmacia Biotech). For electrophoretic mobility gel
shift assays the following oligonucleotides (5
 
 
 
 to 3
 
 
 
, the consen-
sus-binding site is underlined) were used as probes: distal NFAT
site of human IL2 promoter: GGAGGAAAAACTGTTTCATA-
CAGAAGGCGT; AP1 binding site: GCGCTTGATGACT-
CAGCCGGAA; Oct1 binding site: GCGATTTGCATTTC-
TATGAAAACCGG (provided by Dr. I. Dusanter, U363
Inserm, Paris, France). NF
 
 
 
B-like from TNF
 
 
 
 promoter:
CCCTGGTCCTGGGAATTTCCCACTCTGG.
Double-stranded oligonucleotides were end-labeled with
(
 
 
 
32
 
P)-ATP and T4 polynucleotide kinase. Binding reactions
were performed in a 20 
 
 
 
l volume containing 10 
 
 
 
g of the nu-
clear extract and 2 
 
 
 
g of poly(dI-dC) in binding buffer (10 mM
Tris, pH 7.5, 80 mM NaCl, 1 mM EDTA, 5% glycerol, and 1
mM DTT). The cold competitor oligonucleotides or Abs for su-
pershift were preincubated for 15 min at 4
 
 
 
C. Approximately 2
ng of the labeled probes were added to the sample and allowed to
bind for 45 min at 4
 
 
 
C. The resulting DNA–protein complexes
were separated by electrophoresis on a 4% non-denaturing gel in
0.5
 
 
 
 Tris/borate buffer for 3 h at 200 V and 4
 
 
 
C. For Western
blot analysis of the protein bound to DNA, following UV cross-
linking, the binding reaction was scaled up to 40 
 
 
 
g of nuclear
extract and 8 ng of labeled probe in a total volume of 40 
 
 
 
l. The
wet gel was UV irradiated on a transilluminator (306 nm) for 20
min and incubated at room temperature for 3 h. After localizing
the DNA–protein complexes, they were excised from the gel,
equilibrated in SDS sample buffer, resolved on a 10% SDS-
PAGE, and transferred to nitrocellulose membranes followed by
immunoblotting with a mAb to Vav1 (UBI).
 
Reporter Assays.
 
The NFAT-luciferase reporter construct
(provided by Dr. O. Acuto, Institut Pasteur, Paris, France) was
derived from the pUBT-luc plasmid and contained the luciferase
gene under control of the human IL-2 promoter NFAT-binding
site (28, 34). Transfections and determination of luciferase activ-
ity were performed as described previously (31).
 
JNK Assays.
 
For JNK assay, JNK1 immunoprecipitated with
goat polyclonal anti-serum to JNK1 (Santa Cruz Biotechnology,
Inc.) was used to phosphorylate the GST-c-Jun 5–89 fusion pro-
tein (c-jun GST, UBI) for 10 min at room temperature. Proteins
were resolved by SDS-PAGE, transferred to nitrocellulose mem-
branes, and phosphorylation was detected by autoradiography.
To control for JNK1 levels the membrane was subsequently im-
munoblotted with anti-JNK1.
 
Reverse Transcription PCR.
 
RBL cells were transfected with
expression vectors encoding Vav1 or deleted Vav1 constructs.
After IgE cross-linking, RNA was extracted and reverse tran-
scribed. PCR was performed using specific primers for rat IL-2
and a house keeping gene GAPDH as described previously (19).
As a positive control rat IL-2 was transcribed in vitro and 1 
 
 
 
l of
a 1:100 dilution of the resulting mRNA was subjected to amplifi-
cation by PCR.
 
Gene Transfer and Calcium Measurements.
 
For virus-mediated
gene transfer experiments into BMMC, the pSFV1 expression
system, Vav1-green fluorescent protein (GFP) constructs, and in-
fection procedure were as described previously (35). All proce-
dures were performed 4 h after the initial infection. Intracellular
calcium levels were measured as described (30). Briefly, cells were
loaded with 16 
 
 
 
M Fura Red (Molecular Probes) in RPMI/2%
FCS media for 45 min at 37
 
 
 
C. The cells were then incubated
with IgE (1 
 
 
 
g/10
 
6
 
 cells) on ice for 1 h and brought to room
temperature for 20 min. The cells were resuspended in Tyrodes/
BSA, and changes in dye fluorescence with time determined by
flow cytometry after stimulation with 30 ng/ml of Ag, with sub-
sequent stimulation by 1 
 
 
 
M thapsigargin. The changes in fluo-
rescence of Fura Red with time, after Ag stimulation, was mea-
sured only for transfected cells (based on a histogram gate
compared with noninfected cells) expressing GFP. The percent-
 
age of GFP
 
 
 
 cells varied from 9 to 24%.
 
Results
 
Prolonged Stimulation of Fc
 
 
 
RI Results in Nuclear Transloca-
tion of Vav1.
 
We wished to confirm and extend the prior
observations of the nuclear localization of Vav1. For these
studies we used the RBL-2H3 mast cell line, which con-
tains a larger cytoplasmic compartment than T cells. Us-
ing confocal imaging, we found that Vav1 exhibited a cy-
toplasmic localization with a distinct exclusion from the
 
nucleus (Fig. 1 A, NS) consistent with our prior obser-
vations (20). After challenge of IgE-sensitized cells with
antigen for a brief period of time (5–15 min, data not
shown), no nuclear localization could be visualized
whereas longer stimulation periods (30 min or more) led
to the movement of Vav1 to the nucleus (Fig. 1 A, S30
and S60). Quantitation of the relative amount of fluores-
cence in the nucleus of RBL cells (determined by DAPI
staining) during stimulation showed that nuclear localiza-
tion started to increase significantly after 30 min of con-
tinuous stimulation. The relative amount of the fluores-
cent signal present in the nucleus increased by over sixfold
in 1 h (stimulated versus unstimulated cells). A similar
 
translocation of Vav1, after prolonged Fc
 
 
 
RI stimulation,
was also observed in primary bone marrow derived mast
cells (BMMC, Fig. 1 B) indicating that this response was 
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also seen in normal mast cells. No staining was detected
when anti-Vav antibody was either depleted with an ex-
cess of Vav before incubation with the cells or incubated
with vav
 
 
 
/
 
 
 
 BMMCs (Fig. 1 B; control and data not
shown). Additionally, we also observed some nuclear
translocation of Vav1 in Jurkat T cells although a low
level of nuclear fluorescence was also detectable in un-
stimulated cells (data not shown). Thus, these results dem-
Figure 1. Vav1 is translocated to the nucleus af-
ter prolonged Fc RI stimulation. DNP-specific
IgE-sensitized RBL cells (A) or BMMCs purified as
described in Materials and Methods (B) were main-
tained in complete medium and were then either
left unstimulated (NS) or stimulated for 30 (S30) or
60 min (S60) with DNP-HSA. The localization of
Vav1 was determined by single section confocal
imaging using an antibody to Vav1 (UBI; 1/500 di-
lution) and a FITC-labeled secondary antibody ( 
Vav). Nuclei were stained in parallel with DAPI
(DAPI) and merged images are on the right panel.
Insets show higher magnification of one stimulated
cell with anti-Vav Ab (green) and the correspond-
ing merged image with DAPI, respectively. On the
control confocal image anti-Vav antibody was de-
pleted on GST-Vav before incubation with the
cells (B, control). 
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onstrate that Vav1 is capable of translocating to the nu-
cleus upon prolonged cell stimulation.
 
The COOH-terminal SH3 Domain of Vav1 Mediates Its
Cytoplasmic Retention.
 
Upon stimulation of antigen recep-
tors, Vav1 localizes to lipid rafts where it interacts with
other tyrosine phosphorylated partners preferentially via its
SH2 domain (6, 20). In contrast, most of the putative nu-
clear partners of Vav1 interact with its COOH-terminal
SH3 domain, an exception is Enx1 which interacts with
the CH domain. Our initial experiments using a Vav1 con-
struct in which the adaptor region (SH3-SH2-SH3) was
deleted, showed a constitutive nuclear localization for Vav1
(data not shown), thus providing a clue for regulatory con-
trol in the COOH terminus of Vav1. This was not due to
the SH2 domain as Vav1 with mutation or deletion of this
domain localized to the cytoplasm (20). Thus, to further
delineate the importance of each SH3 domain to the nu-
clear localization of Vav1 we constructed Vav1 genetic
mutants where either the NH
 
2
 
- or COOH-terminal SH3
domain was deleted (delNSH3 and delCSH3, respectively,
Fig. 2 A). The mutant constructs were transfected into
RBL-2H3 cells and their subcellular distribution was visu-
alized by confocal imaging (Fig. 2 B). The delNSH3 mu-
tant showed cytoplasmic localization in resting cells and a
partial nuclear translocation upon Fc
 
 
 
RI stimulation similar
to the actions of transfected wt or endogenous Vav1 (Fig. 2
C, Wt-Vav, and Fig. 1 A). Some cytoplasmic accumulation
was also seen in cells expressing the highest levels of exoge-
nous proteins (Figs. 2 B, delNSH3 [S], and 2 C, Wt-Vav
[S]). In contrast, the delCSH3 mutant exhibited a strong
nuclear localization both in unstimulated and stimulated
cells (Fig. 2 B). Immunochemical analysis revealed almost
equivalent expression levels of the mutant and wt proteins
in total extracts and confirmed the increase of delCSH3
Vav1 in nuclear fractions of unstimulated cells compared
with untransfected or wt transfected RBL cells (data not
shown). Because delCSH3 was constitutively localized to
the nucleus, this enabled us to explore the function of the
putative nuclear localization signal sequences (delNLS1 and
delNLS2, respectively) in causing the nuclear localization
of this protein. The first NLS is located within the PH do-
main of Vav1 and is closely related to the SV40 consensus
sequence (Fig. 2 A, NLS1: KXRXXKKK; reference 36).
The second NLS is located between the cysteine rich and
the N-SH3 domains and is composed of a bipartite
sequence (NLS2: KKXKXXRRXXXKKR, resembling
those found in transcription factors [37, 38]). Fig. 2 C
shows that deletion of NLS1 was sufficient to restore a
constitutive cytoplasmic localization to the double mutant
protein (delNLS1delCSH3) whereas deletion of the second
NLS (delNLS2delCSH3) caused this protein to remain in
the nucleus. Similarly, a NLS1 deleted mutant of wt-Vav
was restricted to the cytoplasm upon prolonged Fc
 
 
 
RI
stimulation (Fig. 2 C, delNLS1). In contrast, a NLS2 de-
leted mutant behaved like wt-Vav1 and was able to translo-
cate to the nucleus after Fc
 
 
 
RI stimulation (data not
shown). These results were confirmed by immunochemical
analysis of the nuclear and cytoplasmic fractions of stably
 
transfected delNLS1 and delCSH3 RBL cells. Indeed,
while delCSH3 was predominantly nuclear, delNLS1 was
exclusively cytoplasmic, regardless of whether cells were
stimulated or not (Fig. 2 D).
 
Functional Properties of Vav1 Mutants with Nuclear and Cy-
toplasmic Localization.
 
We previously demonstrated that
the absence of Vav1 in mast cells had significant conse-
quences in the activation of c-Jun NH
 
2
 
-terminal kinase
(JNK1), PLC
 
 
 
, and subsequent calcium responses upon
stimulation of the Fc
 
 
 
RI (19). The calcium regulating ef-
fects of Vav1 were demonstrated to be dependent on the
guanine nucleotide exchange activity of its DH domain.
Therefore, the calcium response of either a cytoplasmic
(delNLS1) or nuclear (delCSH3) localized mutant form of
Vav1 was tested in order to determine their ability to po-
tentiate the calcium influx. To test the effect of these mu-
tants on early activation signals we used BMMC derived
from 
 
vav1-null
 
 mice. Calcium levels were determined in
Fura-Red loaded cells that were reconstituted with wt or
mutant Vav1, gated for transfected GFP expression, and ac-
tivated by Fc
 
 
 
RI stimulation. As shown in Fig. 3 A, we
confirmed our previous results showing a substantial de-
crease in the Ag-dependent calcium response of Vav1-null
BMMCs compared with cells derived from 
 
vav1
 
 
 
/
 
 
 
 mice
(Fig. 3 A, Wt and KO; reference 19). Transfection of
vav1
 
 
 
/
 
 
 
 BMMCs with wt Vav–GFP resulted in a calcium
response that was enhanced, albeit slightly delayed, when
compared with endogenous Vav (KO [Vav-GFP], Wt
[GFP]). In contrast, the delNLS1-Vav mutant (delNLS1)
did not restore any Ag-dependent calcium response, show-
ing levels similar to that observed for 
 
vav
 
 
 
/
 
 
 
 BMMCs
whereas the delCSH3 mutant partially restored the Fc RI-
induced calcium response up to the level of vav /  BMMCs,
albeit with a significantly delayed response to Ag (delCSH3).
Consistent with our prior results (19), the thapsigargin-
induced calcium response, which is independent of Fc RI
engagement, was confirmed to be dependent on Vav1 com-
petence. Both the delNLS1 and delCSH3 mutants showed
reconstitution of the thapsigargin-induced calcium response
to the extent of vav /  derived cells but significantly di-
minished compared with vav /  and wt-Vav transfected
vav /  cells. This result is consistent with an important role
for a fully functional Vav1 in the regulation of calcium
stores.
Vav1 mutants were also tested for their capacity to acti-
vate JNK; another well-documented pathway regulated by
Vav1. For these experiments we used RBL cells, as the effi-
ciency for transfection of vav1 /  BMMCs did not permit
biochemical analysis of JNK activation. The RBL cells were
stably transfected with wt-Vav or mutated Vav and JNK ac-
tivity was measured in an in-gel kinase assay by phosphory-
lation of GST-c-jun. In agreement with previous observa-
tions (11, 39) we observed a substantial induction of JNK
activity in wt Vav1 transfected compared with mock-trans-
fected cells, after antigenic stimulation (Fig. 3 B, WtVav1
versus control GFP). Similarly, although expression levels of
the delNLS1 Vav1 mutant were lower compared with wt
Vav1, it also enhanced to a similar extent JNK activity.1120 Vav1 Is Present in Nuclear Transcriptional Complexes
Conversely, the delCSH3 Vav1 mutant only mildly en-
hanced JNK activation above the control GFP transfectant.
However, this enhancement was significantly less (around
twofold less) than the JNK activation induced by delNLS1
mutant Vav1, although the levels of mutant protein were
higher and JNK1 protein levels were equivalent.
As Vav1 was demonstrated to be important for the acti-
vation of the NFAT transcription factor and IL-2 gene
transcription, we also examined the effect of Vav1 localiza-
tion on NFAT activity. For this purpose, wt Vav,
delCSH3Vav, and delNLS1Vav, were transfected into Jur-
kat T cells together with a luciferase reporter construct un-
Figure 2. Nuclear localization of Vav1 is dependent on a functional nuclear local-
ization signal (NLS1) and is regulated by its COOH-terminal SH3 domain (CSH3).
(A) Mutant forms of Vav1 used in this study. The two putative nuclear localization
sequences of Vav1 are indicated above the schematic representation of Vav1 subdo-
mains (see Materials and Methods). The sequence within the frames of NLS1 and
NLS2 represents the deleted sequences of delNLS1 and delNLS2 mutants. Regions
of deletions for all other mutants are indicated by amino acid sequence listed as num-
bers above the site of deletion. (B) Confocal image analysis of NH2-terminal or
COOH-terminal SH3 deleted Vav1: RBL cells were transfected with either myc-
tagged Vav1 deleted of the N- (delNSH3) or COOH-terminal (delCSH3) Src ho-
mology 3 domain. Cells were either not stimulated (NS) or stimulated for 60 min (S)
and processed for confocal image analysis and staining with mAb to myc (1/500). (C)
Confocal image analysis of full-length wt-Vav-Myc tagged (Wt-Vav) or the NLS1 (delNLS1), NLS1 and CSH3 (delNLS1CSH3), or NLS2 and CSH3
(delNLS2CSH3) deleted Vav1-myc tagged mutants. Unstimulated (NS) or 60 min stimulated (S) RBL cells transfected with the corresponding constructs
were processed for confocal analysis using a mAb to myc. (D) Immunoblot analysis of Vav1 present in nuclear and cytoplasmic fractions. RBL cells stably
transfected with either myc-delNLS1 or myc-delCSH3 constructs were either left unstimulated (NS) or were stimulated (S). Nuclear (Nu) and cytoplas-
mic (Cy) fractions were prepared and aliquots (10  g) were examined by immunoblotting using mAb to myc.1121 Houlard et al.
der control of three repeats of the human IL2 distal pro-
moter NFAT/AP1 binding sites. As shown in Fig. 3 C,
CSH3-deleted Vav1 was very poor in potentiating the
NFAT/AP1-dependent transcriptional activity both in un-
stimulated or CD3 plus CD28 stimulated cells compared
with wt Vav1. In contrast, deletion of the NLS1 sequence
of Vav1 gave similar reporter activity compared with wt-
Vav1 transfected cells. We further corroborated this defect
on reporter activity by directly analyzing the steady-state
levels of IL-2 mRNA in RBL cells transfected with either
wt-Vav, delCSH3 or delNLS1 mutants, or mock DNA.
While the transcription of a housekeeping gene (GAPDH)
was not affected by the different transfectants, overexpres-
sion of wt-Vav1 led to a large increase in IL-2 mRNA ex-
pression upon IgE cross-linking (Fig. 3 D). In contrast,
delCSH3 transfectant exhibited levels of IL2 mRNA even
lower than untransfected or mock-transfected cells. How-
ever, delNLS1 mutant showed some increase of this
mRNA upon Fc RI stimulation. These results show that
transfection of the nucleus-localized delCSH3 Vav1 caused
a delay in the calcium response, failed to elicit substantial
JNK activation, and did not cause the production of IL2
mRNA upon Fc RI stimulation. Expression of the cyto-
sol-localized delNLS1 Vav1 failed to mobilize calcium be-
yond the low levels seen in Vav1-deficient mast cells, al-
though JNK activation appeared equal to that seen by
expression of wt-Vav1. Thus, these findings suggest that
low levels of calcium but full JNK activation are sufficient
to potentiate the NFAT/AP1 DNA reporter activity and
cause some activation of IL2 transcription.
Vav Is Part of Transcriptionally Active Complexes. Be-
cause of our earlier observations of Vav1 localization to the
nucleus and the ability of the cytosolic delNLS1 Vav1 to
drive NFAT/AP1 dependent reporter activity we further
explored whether Vav1 was directly involved in NFAT-
dependent transcriptional activation. We first measured the
induction of nuclear NFAT/AP1 DNA binding activity
upon Fc RI stimulation of RBL cells. The initial kinetic ex-
periments measured the appearance of an NFAT complex in
nuclear extracts that bound the distal site of the human IL-2
promoter. While we observed a slight induction of NFAT
binding activity at 5 min after stimulation, the activity fur-
Figure 3. The differential lo-
calization of Vav1 (delCSH3
versus delNLS1) promotes or in-
hibits functional responses. (A)
Intracellular calcium measure-
ments. Vav  /  (Wt) and  / 
(KO) BMMCs were transfected
with GFP alone (GFP), wt Vav-
GFP (Vav-GFP), delCSH3 Vav-
GFP (delCSH3), and delNLS1
Vav-GFP (delNLS1). Intracellu-
lar calcium levels of IgE and Fura
Red AM loaded cells were mea-
sured by flow cytometry before
and after stimulation at the indi-
cated time (arrows) with 30 ng
DNP-BSA (Ag) followed by 1
 M thapsigargin (Thpsg). Data
were collected after gating of
transfected GFP-positive cells.
One representative calcium ex-
periment is shown. (B) Activa-
tion of JNK activities. RBL cells
were transfected with the indi-
cated constructs. Cells were left
unstimulated ( ) or were anti-
gen stimulated ( ). JNK1 kinase
activity was measured by an in
vitro kinase assay. The top panel
shows an autoradiography of
( 32P) incorporated into c-Jun-
GST after its phosphorylation by
JNK1 immunoprecipitates from
cell lysates. Bottom panels show
the amount of JNK1, exogenous, and endogenous Vav1 found in the transfectants. The fold induction of JNK activity is relative to control GFP (-Ag)
arbitrarily set to 1.0 and is the mean of three individual experiments with standard deviations ranging from 4.3 to 9.9%. (C) Transcriptional activation of
NFAT by Vav1 deletion mutants. Jurkat T cells were cotransfected with the IL-2 promoter-luciferase plasmid and expression plasmids encoding either
wt Vav (wtVav), delCSH3, or delNLS1 Vav mutants. After 24 h, cells were either left unstimulated (NS) or were stimulated for 60 min with CD3 and
CD28 (S). Luciferase activity was determined in cell extracts (top panel). Results are representative of three individual experiments and error bars repre-
sent standard deviation. Samples of the same lysates were also analyzed for the expression of myc-tagged Vav1 constructs by immunoblotting with mAb
to myc (bottom panel). One single representative experiment is shown. (D) Effect of Vav1 deletion mutants on IL-2 steady-state mRNA level. RBL cells
were untransfected (RBL) or transfected with the indicated constructs. Cells were left unstimulated (NS) or were antigen stimulated for 1 h (S). Cytokine
(IL-2) or housekeeping gene (GAPDH) mRNA levels were determined by RT-PCR as described in Materials and Methods. IL-2 control represents the
PCR amplification of in vitro transcribed IL-2 mRNA as a control for IL-2 primers and PCR conditions. One representative of four experiments is shown.1122 Vav1 Is Present in Nuclear Transcriptional Complexes
ther increased reaching a maximum at 1 h (Fig. 4 A). Com-
plex formation was blocked both by NFAT or AP1 unla-
beled competitor oligonucleotides. Interestingly, the kinetics
of NFAT/AP1 DNA binding activity was found to be strik-
ingly similar to the movement of Vav1 to the nucleus.
Hence, we further analyzed the composition of the protein–
DNA complex by electrophoretic mobility supershift assays.
Surprisingly, in addition to the supershift of the NFAT/AP1
binding complex by incubation with anti-NFATp or anti-
c-Jun antiserum, we found that the complex with lower
mobility could be supershifted, or was partly disrupted, by
incubation with two different antibodies to Vav1. An irrele-
vant antibody to GST did not cause this shift (Fig. 4 B, top
left). The presence of Vav in this complex was subsequently
confirmed by UV cross-linking of the lower mobility com-
plex, which was then excised resolved by SDS-PAGE, and
probed by immunoblot with an antibody to Vav1. A specific
band corresponding to p95 Vav was isolated from an excised
region containing the complex induced by Fc RI stimula-
tion (Fig. 4 B, *lane 2), but not from an excised region cor-
responding to the same molecular mass but derived from
unstimulated cells (Fig. 4 B, *lane 1, bottom left). Further-
more, in RBL cells stably transfected with wt Vav1 we
found enhanced formation of the lower mobility NFAT/
AP1 complex (Fig. 4 B, top right). The protein–DNA com-
plex was again supershifted upon incubation with antibodies
to NFATp or Vav but not with antibodies to NFATc or the
irrelevant protein GST. Analysis by Western blotting of the
band of lower mobility also revealed higher quantities of p95
Vav (Fig. 4 B, bottom right, *lane 4).
The NFAT distal site present in the IL-2 promoter has
been shown to cooperatively bind NFAT and AP1 tran-
scription factors (34; Fig. 4 A). The possibility that Vav1
could also participate independently in AP1-DNA binding
was explored by testing an NFAT-independent AP1 site
derived from the human metallothionein IIA promoter. As
shown in Fig. 4 C, nuclear extracts from unstimulated cells
showed a faint but specific protein–DNA complex in a gel
shift assay. The amount of the low mobility complex was
enhanced after Fc RI stimulation and was supershifted
upon incubation with antibody to c-Jun. However, incuba-
tion with antibodies to Vav1 (Fig. 4 C) or NFAT (data not
shown) did not cause a supershift. We further analyzed the
protein-DNA complex (Fig. 4 C, *lanes 1 and 2) for Vav1
Figure 4. Vav1 is a specific
component of NFAT and
NF B-like DNA binding com-
plexes. (A) Kinetics of NFAT
nuclear binding activity present
in nuclear extracts after stimula-
tion of RBL for the indicated
times as revealed by EMSA. The
distal NFAT site of human IL-2
promoter was used as a probe.
The presence of the NFAT-
DNA complex is indicated by an
asterisk. In competition experi-
ments the unlabeled oligonucle-
otides (IL-2 NFAT or AP1 sites,
excess of 20-fold) were incu-
bated 15 min with the nuclear
extract before addition of the
probe. (B–E) Supershift analysis
of various nuclear transcriptional
complexes in unstimulated (NS)
and in stimulated (S) RBL cells
or transfectants (wt-Vav) is
shown. The following different
oligonucleotides were used as
probes: human NFAT (B), AP1
(C), NF B-like (D), and Oct 1
(E). The specific DNA–protein
complexes generated are indi-
cated by an asterisk. For super-
shift analysis extracts were incu-
bated with the following
antibodies: anti-NFATp (UBI)
or NFATc (Santa Cruz Biotech-
nology, Inc.), anti-Vav (a and b:
mAb UBI and pAb provided by
Dr. X. Bustello, respectively),
anti c-Jun and irrelevant anti-
GST or anti-myc for 15 min before addition of the labeled oligonucleotides. Nuclear extracts were also preincubated with an excess (20 ) of unlabeled
competitor oligonucleotide as indicated. In preparative experiments specific complexes (*) were cut out from wet gels using samples corresponding to the
indicated lanes after UV irradiation. Samples were resolved by SDS-PAGE and analyzed by immunoblotting with mAb to Vav1 (bottom of B, C, and D).
Total extracts of RBL were loaded in parallel as controls for immunoblotting (Ext).1123 Houlard et al.
content by UV cross-linking and Western blotting; no band
corresponding to the 95 kD Vav1 was detected (Fig. 4 C,
bottom). The results demonstrate that Vav1 cooperatively
participates in a NFAT/AP1 transcriptionally active com-
plex that specifically binds to the distal region of IL-2 pro-
moter, but not to an NFAT-independent AP1 complex.
The participation of Vav1 in a transcriptionally active com-
plex raised the possibility that it may also participate in other
complexes, like NF B, where Vav1 activity has been dem-
onstrated to play a role (18). We showed previously that an
NF B-like factor binding to an NF B site present in the 3 
region of the TNF-  gene is important for transcriptional
induction of cytokines in mast cells (29). Furthermore, we
also demonstrated that Vav1-deficiency has a partial effect
on the Fc RI-induced TNF-  mRNA levels (19). Thus, it
seemed possible that Vav1 might also form part of a NF B-
like complex in mast cells. As shown in Fig. 4 D, a NF B-
like DNA binding activity, which was weakly detected in
unstimulated cells, was strongly induced upon Fc RI stimu-
lation (Fig. 4 D, *). The resulting protein-DNA complex
was supershifted by incubation with two different antibod-
ies to Vav but not with an anti-Myc Ab (Fig. 4 D, top).
The presence of Vav1 in the bands with lower mobility was
also analyzed. The UV cross-linked proteins in the excised
gel bands were resolved by SDS-PAGE and subsequently
immunoblotted with an antibody to Vav1 revealing the
presence of p95 Vav in these complexes with a detectable
increase during stimulation (Fig. 4 D, lanes 1 and 2, bot-
tom). Finally, we also examined the possible contribution of
Vav1 to another protein–DNA complex corresponding to
the Oct1 site of the IL-2 promoter (40). In unstimulated
cells a rather strong DNA binding protein complex was ob-
served. Increased DNA binding was induced by Fc RI
stimulation. However, incubation with an antibody to
Vav1 failed to supershift this complex (Fig. 4 E). Thus,
while Vav1 can participate cooperatively or independently
in two transcriptionally active complexes (NFAT/AP1 and
NF B-like), its participation is complex specific, as it does
not participate in other transcriptional complexes (AP1 and
Oct1) that also bind the IL-2 promoter.
Nuclear delCSH3 Vav1 Hinders the Formation of Both
NFAT and AP1-DNA Binding Complexes. To under-
stand the failure of delCSH3 Vav1 to potentiate NFAT/
AP1 reporter activity and increase IL-2 mRNA levels, we
analyzed its effect on NFAT/AP1 and AP1 DNA binding
activities in stable delCSH3 transfectants. These results
were compared with cells that had been stably transfected
with either wtVav or delNLS1 Vav1. As shown in Fig. 5 A,
upon Fc RI stimulation, untransfected cells exhibited a
NFAT/AP1-DNA binding activity detected in a gel shift
assay using an NFAT/AP1 oligonucleotide probe. This
complex was enhanced in the cells overexpressing wt-Vav1
(compare wt-Vav and RBL). Similarly, untransfected and
stimulated RBL cells exhibited an enhanced NFAT-inde-
pendent AP1 DNA binding activity (Fig. 5 A, RBL, AP1).
Again, overexpression of wt-Vav1 resulted in a strong en-
hancement of the AP1 binding complex that was readily
seen in unstimulated cells and further increased with Fc RI
stimulation (AP1, wt-Vav). Immunoblot analysis with an
antibody to NFATp, confirmed the substantial increase of
NFAT in the nucleus of wt-Vav1 cells compared with un-
transfected cells after stimulation (Fig. 5 A, bottom). In
striking contrast, in the cells that had been stably transfected
with the constitutively nuclear-localized delCSH3 Vav1
mutant we did not detect a functional NFAT/AP1 DNA
binding activity in three separate stably transfected clones
even after prolonged exposures (Fig. 5 A, delCSH3 and
data not shown). Furthermore, while a weak AP1 DNA
binding activity was detected in unstimulated cells, the
binding was not increased upon stimulation. Thus,
delCSH3 Vav1 was ineffective in potentiating both
NFAT/AP1 and AP1 DNA binding activities and in in-
creasing IL-2 mRNA (Fig. 3 D).
In contrast, in nuclear extracts of cells transfected with
delNLS1 we could identify an AP1 DNA binding activity,
comparable to wt-Vav transfected cells, that was enhanced
Figure 5. Differential effect of
Vav1 constructs expression on
nuclear transcriptional com-
plexes in RBL cells. (A and B)
Nuclear extracts from RBL cells
untransfected or transfected with
wt-Vav myc-tagged (wt-Vav),
delCSH3-Vav or delNLS1-Vav,
and either unstimulated (NS) or
60 min stimulated (S) were in-
cubated with the indicated dou-
ble stranded ( 32P)-labeled oli-
gonucleotides. Autoradiography
with delCSH3 extracts were
subjected to longer exposures to
maximize the detected signals.
Nuclear extracts were also pre-
incubated with unlabeled com-
petitor oligonucleotide for spec-
ificity control as indicated. (A, bottom panel) Quantified nuclear extracts (10  g) of the cells were analyzed by immunoblotting with mAb to NFATp
(UBI) or as a loading control with mAb to PARP (Santa Cruz Biotechnology, Inc.).1124 Vav1 Is Present in Nuclear Transcriptional Complexes
upon stimulation. However, the NFAT/AP1 DNA binding
activity observed, although slightly enhanced upon stimula-
tion, remained very weak and became apparent only after
prolonged exposure (Fig. 5 A, delNLS1). This is consistent
with the inability of delNLS1 Vav1 to effectively translocate
to the nucleus and to promote IL-2 mRNA accumulation
to the level of wt Vav1 (see Fig. 5 A, RBL, and Fig. 3 D).
Immunoblot analysis of the nuclear extracts of delCSH3 or
delNLS1 cells revealed a slight increase in the quantity of
NFAT present in the nucleus upon stimulation to the same
extent as untransfected RBL cells (Fig. 5 A, bottom). Thus,
this increase in all three nuclear extracts is likely attributed
to the presence and activation of endogenous Vav1. Finally,
the appearance of an Oct1 nuclear complex was not affected
by any of the Vav1 constructs as its DNA-binding activity
was present in unstimulated cells and was similarly further
enhanced by Fc RI stimulation (Fig. 5 B).
As the delCSH3 Vav1 mutant does not seem to affect the
nuclear translocation of NFAT mediated by endogenous
Vav1, we analyzed whether its inhibitory effects on NFAT
and AP1 DNA binding activities were related to the quan-
tity of the mutant protein present in the nucleus. We used
two additional delCSH3 stable clones expressing lower levels
of the nuclear myc-tagged delCSH3 as monitored by immu-
noblotting of nuclear extracts with anti-Myc antibody (Fig.
6 B, clones 1 and 2). Nuclear extracts from these transfec-
tants demonstrated an inhibitory effect on both NFAT/AP1
and AP1 DNA binding activities compared with endoge-
nous Vav 1 in untransfected RBL cells. The inhibitory effect
was proportional to the amount of delCSH3 Vav present in
the nucleus, leading to complete inhibition of complex for-
mation in the highest expressing clone (clone 3; Fig. 6 A).
Together with the data from the previous section these
results indicate that delCSH3 Vav1 is unable to promote
the formation of an NFAT/AP1-dependent transcription-
ally active complex. They also demonstrate that this nuclear
mutant hinders the DNA binding mediated by endogenous
Vav1 and has a more general inhibitory effect as exempli-
fied by inhibition of AP1 DNA binding.
Discussion
Vav 1 contains multiple protein structural interaction
motifs that have allowed the isolation of several binding
partners in vitro and in vivo, indicating a role for Vav1 as
an adaptor in a wide variety of signaling pathways. Among
the structural domains found on Vav1, the COOH-termi-
nal SH3 domain has been most exclusively associated with
nuclear proteins. However, the functional relevance of
these interactions is unknown (23–25).
In this report we demonstrate that the COOH-terminal,
but not the NH2-terminal, SH3 domain of Vav1 is directly
responsible for the cytoplasmic retention of the proto-onco-
gene. Although the mechanism remains unknown, one
possibility may be that the COOH-terminal SH3 mediates
specific interaction with cytoskeletal proteins that sequester
it in the cytoplasm (27, 41). Furthermore, SH3-dependent
interaction with other cytoplasmic proteins could also pre-
vent its movement to the nucleus as described for NF B/
I B complexes interacting with RasGAP SH3-binding
proteins (42). Alternatively, the C-SH3 domain or the
COOH-terminal portion of Vav may also be responsible for
intramolecular bridging that could mask the NLS within the
PH domain. This mechanism of intramolecular masking of
an NLS was previously described in the nuclear transport of
B-Myb (43). Our data support the unmasking of the NLS
upon Fc RI stimulation, as the deletion of the functional
NLS1 sequence restored retention of the delCSH3 mutant
and Vav1 in the cytoplasm. Although deficient in nuclear
transport, the delNLS1 Vav1 mutant was still capable to ac-
tivate JNK, an event that requires both the tyrosine phos-
phorylation of Vav1 and the conformational activation of
the DH domain (44–46). Genetic studies have indicated a
major role for Vav1 both in early signaling events such as in
calcium mobilization and cytoskeletal rearrangement but
also in more delayed responses, such as the production of
Figure 6. A concentration-dependent negative regulatory effect of nu-
clear delCSH3 Vav1 on transcription complex formation. Nuclear ex-
tracts from untransfected RBL cells (RBL) and three independent clones
of stably transfected RBL cells (del CSH3, cl1, cl2, and cl3), expressing
varying concentrations of delCSH3, were analyzed for their effect on for-
mation of transcription complexes. (A) Nuclear extracts from unstimu-
lated ( ) or 60 min stimulated ( ) cells were incubated with the indi-
cated double-stranded ( 32P)-labeled oligonucleotides (AP1 or human
NFAT) and analyzed by EMSA. (B) Nuclear extracts (10  g) of the
delCSH3 clones were analyzed by immunoblotting with mAb to Myc to
titrate for the relative amounts of the Myc-delCSH3 Vav 1 proteins.
Control of the loading was performed by subsequent immunoblotting
with mAb to PARP (Santa Cruz Biotechnology, Inc.).1125 Houlard et al.
cytokines, including IL-2, IL-3, IFN- , and TNF- . Ex-
perimental evidences have focused on the role of Vav1 as a
guanine nucleotide exchange factor (GEF) for Rac and the
consequences of Rac activation on cytokine production.
More recently, however, several reports described a guanine
nucleotide exchange factor-independent function of Vav1,
most notably in potentiating NFAT transcriptional activity
and facilitating PLC  phosphorylation (19, 47). Our find-
ings provide strong evidence for GEF-independent regula-
tion of NFAT as Vav1 is demonstrated to become an active
participant in the NFAT/AP1 transcriptional complex that
binds to the distal promoter of IL-2. Indeed, supershift anal-
ysis of the activated complex, using two different antibod-
ies, established the presence of Vav1. Interestingly, a third
antibody directed to the C-SH3 domain of Vav1 was un-
able to supershift the complex indicating that this domain
may be inaccessible because of the conditions used in the
gel shift assays or because it may be bound to another pro-
tein (unpublished data). The specific presence of Vav1
within the complex was also confirmed by direct immu-
nochemical analysis. The importance of Vav1 in the forma-
tion of NFAT/AP1 complex is also reinforced by our data
that shows a substantial enhancement of both the DNA-
bound complex and all identified components, including
Vav1, in cells overexpressing wt Vav (see Figs. 4 B and 5
A). On the other hand, we did not observe its presence in a
protein–DNA complex containing only the AP1 transcrip-
tion factor-binding site, despite a strong induction of AP1
binding activity upon Fc RI stimulation. Vav1 was also ab-
sent in the NFAT-independent Oct1 transcriptional com-
plex activated upon Fc RI stimulation but was present in
another inducible NF B-like transcriptional complex that
has been shown to play a role in the transcription of TNF 
in RBL mast cells (29). These results clearly favor the spe-
cific interaction of Vav1 with NFAT and NF B complexes
and are in agreement with the impaired NFAT and NF B
activation previously observed in vav1 /  animals (18).
Thus, beyond the ability of Vav to lead to NFAT and
NF B activation we found that Vav1 becomes a potentiat-
ing partner of the transcriptionally active complex.
To further explore the mechanisms involved we ex-
ploited the findings that deletion of specific motifs or
domains of Vav1 would result in opposite cellular com-
partmentation under nonactivation conditions. The cyto-
plasmic delNLS1 Vav1 mutant that was still fully effective
in activating JNK showed a strong NFAT-independent
AP1–DNA binding activity and a weak AP1-binding to
the NFAT/AP1 probe. However, this mutant was in-
effective at potentiating calcium influx, and, accordingly,
NFAT nuclear translocation and DNA binding were not
enhanced over endogenous levels. This suggests that in-
creased JNK activation alone was not sufficient to enhance
NFAT binding. Despite the absence of significant NFAT/
AP1 mobilization the delNLS1 Vav1 strongly induced a
NFAT/AP1 reporter activity after transient transfection
into Jurkat cells and led to some increase of the levels of
IL2 mRNA in RBL cells. This result is most easily ex-
plained by the binding of AP1 to the three NFAT/AP1
tandem repeats present in the reporter plasmid. This is in
agreement with a recent study that has revealed an AP1-
dependent induction of this IL-2 reporter construct (48).
Our competition experiments using the AP1 recognition
motif also confirmed the ability of AP1 to bind to the IL-2
distal promoter in the absence of NFAT and to promote
some transcriptional activation of the IL-2 gene (Figs. 4 A
and 3 D). Collectively, the results with the delNLS1 Vav1
mutant provide further evidence for a model whereby
Vav1 has GEF-dependent and -independent activities that
must function synergistically to promote maximal NFAT/
AP1 binding activity at the IL-2 distal promoter and drive
full gene transcription (47). The inability of the delNLS1
mutant to potentiate calcium influx might further reflect
some alteration within the PH domain that inhibits Vav1-
mediated activation of PLC  and PI3K, the latter activity
being necessary for thapsigargin-induced depletion of ER
stores (19, 49, 50). This hypothesis is further reinforced by
a subcellular localization of the delNLS1 mutant that is
more diffuse in the cytoplasm and does not rapidly localize
to the plasma membrane at early time of stimulation as
compared with wt-Vav (Fig. 2 C, and data not shown).
The constitutive and primarily nuclear localization of the
delCSH3 Vav1 mutant allowed us to assess the effects of its
presence in the nucleus. Clearly, this mutant, in contrast to
wt-Vav1, was unable to induce luciferase activity with an
IL-2 promoter construct and to promote the transcription
of this cytokine gene. However, the novel finding was that
this mutant, in a dose dependent manner, was ineffective in
inducing detectable levels of both NFAT/AP1 and AP1-
DNA complexes by endogenous Vav (see Figs. 5 A and 6
A). As delCSH3 also inhibited induction of AP1 com-
plexes, where Vav is not a participant, this suggests a more
general inhibitory effect for this mutant. This hypothesis is
in agreement with our finding that the inducible NF B-
like DNA complex, in which Vav1 is a component, is also
abrogated in delCSH3 transfected cells (unpublished data).
Because del-CSH3 Vav1 does not induce further NFAT
translocation but does not abrogate NFAT translocation
due to endogenous Vav, it does not appear that the
delCSH3 mutation affects transport of transcription factors
into the nucleus. However, the absence of the C-SH3 do-
main is the characteristic in common to the inhibitory effect
on NFAT, NF B, and AP-1 DNA binding activity. One
possibility, in agreement with our results of a delCSH3-
mediated dose-dependent inhibitory effect is that increasing
concentrations of delCSH3 largely accumulated in the nu-
cleus, can compete for the binding of endogenous Vav1 to
these transcriptional complexes thereby sequestering them
as a complex unable to bind to its DNA. Our current hy-
pothesis is that Vav plays the role of an adaptor protein in
the nucleus as it does in the cytoplasm and that this role is
important for the DNA binding activity of transcriptional
complexes. It is already known that the C-SH3 domain as-
sociates with Ku70, a component of the DNA-dependent
protein kinase complex, and Ku70 interactions with ho-
meobox transcription factors (known as important effectors
in the hematopoietic system) have been described (23, 51).1126 Vav1 Is Present in Nuclear Transcriptional Complexes
Thus, it is possible that Vav1 plays a more general role in
the nucleus by facilitating the phosphorylation and/or as-
sembly of transcription factor–containing DNA binding
complexes. Interestingly, the full transcriptional activity of
NFAT seems to require phosphorylation of the NH2-ter-
minal transactivation domain by an inducible kinase (52). It
is also of interest to note that Vav1 associates with ENX-1
(26), a putative regulator of homeobox gene expression.
In conclusion, this study provides direct evidence for the
presence of Vav1 as a component of an active transcrip-
tional complex. It demonstrates the participation of Vav1
in an NFAT and NF B-like transcriptional complex but
not as a member of AP-1 or Oct DNA binding complexes.
Furthermore, we found that the presence of Vav1 in the
nucleus is promoted by the prolonged stimulation of recep-
tors and depends on a functional NLS found within the PH
domain of Vav1 as well as on derepression of the C-SH3
domain-mediated cytoplasmic localization. This provides
the first evidence of a nuclear role for Vav1 and further
demonstrates that its role in regulation of IL-2 gene tran-
scription transcends the regulation of calcium responses and
JNK stimulation that activate NFAT.
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